IRVING, Texas--(BUSINESS WIRE)--When it comes to determining how the heart is functioning or whether cancer is present, doctors and patients rely on diagnostic tests using a radioactive medical-grade isotope made from Molybdenum-99 (Mo-99) which is historically produced using highly-enriched uranium (HEU), an extremely dangerous substance used in nuclear weapons. The National Nuclear Security Administration’s (NNSA) 2015 Mo-99 Topical Meeting, hosted by Argonne National Laboratory and held in Boston, Massachusetts from Aug. 31-Sept. 3, 2015, brought together international and domestic policy and technical experts to present and discuss progress toward achieving the production of Mo-99 without the use of HEU. Invited to present at the meeting, Novation supports efforts encouraging the adoption of processes that create a reliable domestic supply of non-HEU Mo-99 for medical grade isotopes used in radiopharmaceuticals.
Leah Gannon, MBA, radiopharmaceutical portfolio executive for Novation, represented the company at the meeting. “Radiopharmaceuticals play a key role in the diagnosis of various disease states and have a complex and fragile supply chain. It was an honor to participate in the Topical meeting to provide information around the barriers to entry in implementing non-HEU Mo-99 into the healthcare supply chain and propose an action plan to overcome those barriers,” said Gannon.
In her role at Novation, Gannon has worked on numerous imaging initiatives with a specific emphasis on radiopharmaceutical distribution and contrast media utilization. She also works with multi-disciplinary provider councils and task forces and is an active member of SNMMI and AHRA.
Novation, a leading healthcare services company, serves the members of VHA Inc., the national health care network of not-for-profit hospitals, UHC, the alliance of the nation’s leading academic medical centers, Children’s Hospital Association, and Provista LLC. Novation is a subsidiary company of VHA and UHC which recently merged to form the largest member-owned and member-driven health care company in the country.
Novation is committed to helping with the non-proliferation of HEU use in the production of radiopharmaceuticals as well as to helping the provider members it serves manage appropriate use of these medical isotopes. Novation’s commitment includes sharing industry-leading best practices, providing active assistance with the development of successful programs, educating members on key medical imaging topics, and using institutional data to drive appropriate change in practice.
Novation is the nation’s leading health care services company, focused on revolutionizing operational performance for more than 100,000 members and affiliates of VHA Inc., UHC, Children's Hospital Association and Provista LLC. Novation’s progressive approach to cost performance, data and intelligence, and integrated advisory solutions helps health care providers envision and advance new models of cost-effective, high-quality care. Headquartered in Irving, Texas, Novation is committed to the highest standards of ethical behavior and twice has been honored with the Ethisphere Institute’s coveted Ethics Inside® Certification, and has been named four years consecutively to Ethisphere’s World’s Most Ethical Companies list.